Alexza's agitation drug gets FDA approval
Dec 21 (Reuters) - Alexza Pharmaceuticals Inc said the U.S. health regulators approved Adasuve, making it the first treatment for schizophrenia and bipolar disorder that can be inhaled.
Adasuve, which delivers an older antipsychotic drug called loxapine, passes through the lungs and into the bloodstream faster than a typical pill. Loxapine is available as an oral drug for schizophrenia.
Three injectable drugs, Bristol-Myers Squibb's Abilify, Eli Lilly's Zyprexa and Pfizer Inc's Geodon, are currently approved to calm patients with schizophrenia or bipolar disorder.
Adasuve, Alexza's most advanced drug, will be available for commercial launch early in the third quarter of 2013, the company said.
Earlier this month, European health regulators recommended approval of Adasuve.
The FDA denied approval to Adasuve in May, after it found deficiencies at the company's Mountain View, California manufacturing facility during an inspection.
Trading in the company's shares was halted at $5.79, down 7 percent, on the Nasdaq on Friday.
- Total CEO de Margerie killed in Moscow as jet hits snow plow |
- Pistorius starts five-year term for killing Reeva Steenkamp
- Sweden gets two new sightings, as hunt for undersea intruder goes on
- Ebola crisis turns a corner as U.S. issues new treatment protocols
- U.S. Congress examining deal between NSA official, ex-agency chief